Echo Therapeutics, Inc. (OTCMKTS:ECTE) is a medical technology company focused on the development and commercialization of noninvasive, wearable biosensor platforms designed to monitor physiological parameters continuously. Originally established to address the need for more accurate assessments of alcohol consumption, the company has since expanded its research to include glucose monitoring applications. Echo’s core mission is to deliver user-friendly devices that provide realtime data for healthcare providers, regulatory agencies, and end users, improving compliance and enabling more informed decision making.
One of the company’s flagship products is the WrisTAS™ transdermal alcohol sensor, which measures ethanol vapor excreted through the skin. Engineered for use in clinical trials, legal and workplace settings, and consumer markets, WrisTAS™ has achieved CE Mark clearance and continues to undergo studies aimed at broader regulatory approvals. The device is designed to offer a discreet, continuous readout of alcohol intake, reducing reliance on blood draws or breath testing and providing a more complete picture of user behavior over time.
Building on its expertise in transdermal sensing, Echo Therapeutics is also developing a noninvasive continuous glucose monitoring (CGM) system. Utilizing reverse iontophoresis technology, the CGM patch is intended to extract and measure glucose molecules from interstitial fluid beneath the skin without the need for finger sticks. Currently in clinical evaluation, the glucose platform seeks to offer an alternative to traditional invasive monitors, addressing a significant unmet need among the growing population of individuals with diabetes.
Headquartered in Pennsylvania, Echo Therapeutics operates research and development facilities in the United States and collaborates with strategic partners across Europe. The company is guided by a management team with decades of experience in medical device innovation, regulatory affairs, and product commercialization. Through ongoing clinical programs and regulatory engagements, Echo aims to expand its product portfolio and establish its wearable biosensor technologies as standards in both the alcohol monitoring and diabetes care markets.
AI Generated. May Contain Errors.
